Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response

• Principais autores: Emilia Alors-Pérez (Autor), Sergio Pedraza-Arevalo (Autor), Ricardo Blázquez-Encinas (Autor), Víctor García-Vioque (Autor), Antonio Agraz-Doblas (Autor), Elena M. Yubero-Serrano (Autor), Marina E. Sánchez-Frías (Autor), Raquel Serrano-Blanch (Autor), María Ángeles Gálvez-Moreno (Autor), Francisco Gracia-Navarro (Autor), Manuel D. Gahete (Autor), Álvaro Arjona-Sánchez (Autor), Raúl M. Luque (Autor), Alejandro Ibáñez-Costa (Autor), Justo P. Castaño (Autor)
• Formato: Livro
• Publicado em: Elsevier, 2024-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Pancreatic neuroendocrine tumors (PanNETs) comprise a heterogeneous group of tumors with growing incidence. Recent molecular analyses provided a precise picture of their genomic and epigenomic landscape. Splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing key tumor...